Globestar Therapeutics Stock Price, News & Analysis
Company Description
Globestar Therapeutics (OTC Link: GSTC) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $124.1K.
GSTC stock has declined 100.0% over the past year. Shares last traded at $0.0000.
This page provides a comprehensive overview of GSTC stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Globestar Therapeutics (GSTC) stock last traded at $0.0000. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $124.1K, GSTC is classified as a micro-cap stock with approximately 1.2B shares outstanding.
Latest News
Globestar Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include clinical trial. View all GSTC news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Globestar Therapeutics (GSTC) currently stands at 37.8 thousand shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Globestar Therapeutics (GSTC) currently stands at 1.4 days, down 52.1% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 37% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
GSTC Company Profile & Sector Positioning
Globestar Therapeutics (GSTC) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing GSTC often look at related companies in the same sector, including Tracon Pharmaceu (TCON), Endonovo Therape (ENDV), Scorpius Holdings (SCPX), Panbela Therapeutics Inc (PBLA), and Trevena Inc (TRVN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GSTC's relative position within its industry.